Nexia sells assets, founder Jeffrey Turner resigns

Guest Contributor
May 3, 2005

Montreal’s Nexia Biotechnologies Inc has sold most of its operations and replaced founder, president and CEO Dr Jeffrey Turner after failing to secure new financing. Nexia sold all its operations and assets related to Protexia — a protein that acts as an antidote to nerve gas — to PharmAthene Inc, Annapolis MD, a private biotech company focused on the development of biodefence therapeutics. Much of the $15.6 million in proceeds will be returned to shareholders. Turner was recently appointed to the advisory committee for Industry Canada’s two pilot commercialization funds (<a class="micro" href="http://">R$, November 22/04). Nexia was once the darling of the Canadian biotechnology industry for its ability to produce proteins using genetically modified goats. The goat herd was sold to PharmAthene….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.